Lexaria Receives USD$2.6 Million Tax Rebate Payment
(PR-inside.com) Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that it has received a cash r…
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


